Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis

Rheumatology

Volumn 49, Issue 7, 2010, Pages 1245-1256

  Tomizawa, Kazuo ^a   Nagao, Tomokazu ^b   Kusunoki, Reina ^b   Saiga, Kan ^c   Oshima, Masamichi ^a   Kobayashi, Kazuo ^a   Nakayama, Toshinori ^b   Tanokura, Masaru ^d   Suzuki, Kazuo ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NIPPON KAYAKU CO LTD   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

15 deoxyspergualin; ANCAassociated glomerulonephritis; MPO ANCA; Rapidly progressive glomerulonephritis; Risk epitopes; SCG Kj mouse

Indexed keywords

15 DEOXYSPERGUALIN; DSG; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; MPO SPECIFIC NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; HEMATURIA; KIDNEY FAILURE; LYMPHOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SPLEEN CELL; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GLOMERULONEPHRITIS; GUANIDINES; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MICE; MICE, INBRED STRAINS; RENAL INSUFFICIENCY;

EID: 77954179652     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq087     Document Type: Article

References (48)

1. Tervaert CJW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titer. Lancet 1990; 336:709-11.
2. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis. Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42: 421-30.
3. Harper L, Williams JM, Savage CO. The importance of resolution of inflammation in the pathogenesis of ANCA-associated vasculitis. Biochem Soc Trans 2004;32: 502-6.
4. Guilpain P, Servettaz A, Batteux F, Guillevina L, Mouthon L. Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. Autoimmun Rev 2008;7:421-5.
5. Neumann I, Birck R, Newman M et al. SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int 2003;64: 140-8.
6. Little MA, Smyth CL, Yadav R et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005;106:2050-8.
7. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-63.
8. Ito-Ihara T, Ono T, Nogaki F et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated papidly progressive glomerulonephritis. Nephron Clin Pract 2005;102:c35-c42.
9. Kinjoh K, Kyogoku M, Good RA. Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 1993;90:3413-7.
10. Ishida-Okawara A, Ito-Ihara T, Muso E et al. Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol Dial Transplant 2004;19: 1708-15.
11. Yumura W, Itabashi M, Okawara A et al. A novel mouse model for MPO-ANCA-associated glomerulonephritis. Microbiol Immunol 2006;50:149-57.
12. Lan HY, Zarama M, Nikolic-Paterson DJ, Kerr PG, Atkin RC. Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. J Am Soc Nephrol 1993;3:1765-74.
13. + B lymphocytes. Clin Exp Immunol 1998;112: 495-500.
14. Hotta O, Furuta T, Chiba S, Yusa N, Taguma Y. Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis. Am J Kid Dis 1999;34: 894-901.
15. Flossmann O, Baslund B, Bruchfeld A et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009;68: 1125-30.
16. Schmitt WH, Birck R, Heinzel PA et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005;20:1083-109.
17. Tomizawa K, Mine E, Fujii A et al. A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants. J Clin Immunol 1998;18:142-52.
18. Fujii A, Tomizawa K, Arimura Y et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCAassociated glomerulonephritis. Clin Nephrol 2000;53: 242-52.
19. Suzuki K, Kobayashi S, Yamazaki K et al. Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol 2007; 51:1215-20.
20. Erdbrügger U, Hellmark T, Bunch DO et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mice MPO chimeras. Kidney Int 2006;69: 1799-805.
21. Van der Geld YM, Huitema MG, Franssen CF, van der Zee R, Limburg PC, Kallenberg CGM. In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 2000;122:504-13.
22. Audrain MA, Baranger TA, Moguilevski N et al. Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. Clin Exp Immunol 1997;107: 127-34.
23. Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCAassociated vasculitides. Nat Clin Pract Rheum 2006;2: 661-70.
24. Gao Y, Ye H, Yu F, Guo X, Zhao M. Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Immunol 2005;117: 87-93.
25. Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005;142:207-15.
26. Floege J, Johnson RJ, Gordon K et al. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 1991;40:477-8.
27. Nemoto K, Mae T, Saiga K, Matsuura E, Koike T. Autoimmune-prone (NZW x BXSB)F1 (W/BF1) mice escape severe thrombocytopenia after treatment with deoxyspergualin, an immunosuppressant. Br J Haematol 1995;91:691-6.
28. Tipping PG, Huang XR, Qi M, Van GY, Tang WW. Crescentic glomerulonephritis in CD4-and CD8-deficient mice. Am J Pathol 1998;152:1541-8.
29. Li S, Holdsworth SR, Tipping PG. Antibody independent crescentic glomerulonephritis in mu chain deficient mice. Kidney Int 1997;51:672-8.
30. Stevens DL, Kaplan EL eds. Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. New York: Oxford University Press, 2000:353-4.
31. Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995;25: 2558-62.
32. Sugawara A, Torigoe T, Tamura Y et al. Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells. Cell Stress Chaperones 2009;14:133-9.
33. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43: 682-92.
34. Bertani T, Abbate M, Zoja C et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989;134:419-30.
35. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumor necrosis factor-alpha. Nephrol Dial Transplant 2001;16:518-24.
36. Karkar AM, Tam FW, Steinkasserer A et al. Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 1995;48:1738-46.
37. Hir ML, Haas C, Marino M, Ryffe B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest 1998;78:1625-31.
38. Ryffel B, Eugster H, Haas C, Hir ML. Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice. Int J Exp Pathol 1998;79: 453-60.
39. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in marine crescentic glomerulonephritis. J Am Soc Nephrol 2003;14: 1785-93.
40. Inaba M, Takahashi T, Kumeda Y et al. Increased basal phosphorylation of mitogen-activated protein kinases and reduced responsiveness to inflammatory cytokines in neutrophils from patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:52-60.
41. Falk RJ, Jennette JC. ANCA are pathogenic - oh yes they are! J Am Soc Nephrol 2002;13:1977-9.
42. Heeringa P, Tervaert JWC. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int 2004;65:1564-7.
43. van der Geld YM, Stegman CA, Kallenberg CGM. B cell epitope specificity in ANCA-associated vasculitis: does it matter? Clin Exp Immunol 2004;137:451-9.
44. Suzuki R, Tomizawa K, Suzuki K, Tanokura M. MPO-ANCA binding site on MPO molecule estimated from epitope mapping study and molecular modeling. Bioimages 2004;12:85-90.
45. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener's granulomatosis and microscopic polyangiitis. Nephrology 2008;13:7629-35.
46. Jennette JC, Falk RJ. Nosology of primary vasculitis. Curr Opin Rheumatol 2007;19:10-6.
47. Gracie JA, Bradley JA. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur J Immunol 1996;26: 1217-22.
48. Tipping PG, Holdsworth SR. T Cells in crescentic glomerulonephritis. J Am Soc Nephrol 2006;17:1253-63.